APA (7th ed.) Citation

Y, M., M, S., S, N., K, S., H, S., R, K., . . . K, K. (2025). Lenvatinib suppress FGF19-FGFR4 signaling to enhance antitumor immune response in gastric cancer. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 28(3), 397. https://doi.org/10.1007/s10120-025-01596-9

Chicago Style (17th ed.) Citation

Y, Maruyama, et al. "Lenvatinib Suppress FGF19-FGFR4 Signaling to Enhance Antitumor Immune Response in Gastric Cancer." Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 28, no. 3 (2025): 397. https://doi.org/10.1007/s10120-025-01596-9.

MLA (9th ed.) Citation

Y, Maruyama, et al. "Lenvatinib Suppress FGF19-FGFR4 Signaling to Enhance Antitumor Immune Response in Gastric Cancer." Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, vol. 28, no. 3, 2025, p. 397, https://doi.org/10.1007/s10120-025-01596-9.